Sodium-Glucose Cotransporter 2 Inhibitors for Mesenchymal-Epithelial Transition Inhibitor-Induced Edema

Overview

Journal Thorac Cancer

Specialties Oncology
Pulmonary Medicine

Date 2024 Dec 13

PMID 39671301

Authors

Takuya Oyakawa

Keita Miura

Nao Muraoka

Kei Iida

Ayano Fujita

Tateaki Naito

Toshiaki Takahashi

Affiliations

Soon will be listed here.

Abstract

The effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors on mesenchymal-epithelial transition factor (MET) inhibitor-induced edema remain unclear. In a patient with tepotinib-induced edema and an N-terminal pro-brain natriuretic peptide (NTproBNP) level ≥ 300 pg/mL, the addition of empagliflozin to loop diuretics reduced the edema. This suggests that empagliflozin may be a treatment option for MET inhibitor-induced edema.

References

Kolwelter J, Kannenkeril D, Linz P, Jung S, Nagel A, Bosch A . The SGLT2 inhibitor empagliflozin reduces tissue sodium content in patients with chronic heart failure: results from a placebo-controlled randomised trial. Clin Res Cardiol. 2022; 112(1):134-144. PMC: 9849317. DOI: 10.1007/s00392-022-02119-7. View

Murashima R, Sai E, Tagawa Y, Yanagawa H, Ishiwata S, Kawaguchi Y . Usefulness of Dapagliflozin for Nephrotic Syndrome Secondary to Diabetic Kidney Disease. Intern Med. 2022; 61(24):3699-3702. PMC: 9841097. DOI: 10.2169/internalmedicine.9121-21. View

Verma S, McMurray J . SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia. 2018; 61(10):2108-2117. DOI: 10.1007/s00125-018-4670-7. View

Veillon R, Sakai H, Le X, Felip E, Cortot A, Smit E . Safety of Tepotinib in Patients With MET Exon 14 Skipping NSCLC and Recommendations for Management. Clin Lung Cancer. 2022; 23(4):320-332. PMC: 10068910. DOI: 10.1016/j.cllc.2022.03.002. View

Anker S, Butler J, Filippatos G, Ferreira J, Bocchi E, Bohm M . Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med. 2021; 385(16):1451-1461. DOI: 10.1056/NEJMoa2107038. View

Solomon S, McMurray J, Claggett B, de Boer R, DeMets D, Hernandez A . Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med. 2022; 387(12):1089-1098. DOI: 10.1056/NEJMoa2206286. View

. The diagnosis and treatment of peripheral lymphedema. Consensus document of the International Society of Lymphology. Lymphology. 2003; 36(2):84-91. View

Paik P, Felip E, Veillon R, Sakai H, Cortot A, Garassino M . Tepotinib in Non-Small-Cell Lung Cancer with Exon 14 Skipping Mutations. N Engl J Med. 2020; 383(10):931-943. PMC: 8422679. DOI: 10.1056/NEJMoa2004407. View

Belli M, Barone L, Bellia A, Sergi D, Lecis D, Prandi F . Treatment of HFpEF beyond the SGLT2-Is: Does the Addition of GLP-1 RA Improve Cardiometabolic Risk and Outcomes in Diabetic Patients?. Int J Mol Sci. 2022; 23(23). PMC: 9737325. DOI: 10.3390/ijms232314598. View

10.

Docherty K, Vaduganathan M, Solomon S, McMurray J . Sacubitril/Valsartan: Neprilysin Inhibition 5 Years After PARADIGM-HF. JACC Heart Fail. 2020; 8(10):800-810. PMC: 8837825. DOI: 10.1016/j.jchf.2020.06.020. View

11.

Tanaka A, Nakamura T, Sato E, Node K . Therapeutic potential of tofogliflozin on nephrotic syndrome secondary to diabetic nephropathy. J Cardiol Cases. 2018; 16(1):30-33. PMC: 6147387. DOI: 10.1016/j.jccase.2017.04.003. View

12.

De Pascalis A, Cianciolo G, Capelli I, Brunori G, La Manna G . SGLT2 inhibitors, sodium and off-target effects: an overview. J Nephrol. 2020; 34(3):673-680. DOI: 10.1007/s40620-020-00845-7. View